CLEC16A

Across TCGA pan-cancer cohorts, CLEC16A RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CLEC16A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where CLEC16A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CLEC16A is over-expressed in tumor, although a few such as KIRC and LUSC show the opposite, repressed pattern.

KIRP, LIHC, and STAD are the cancer types where CLEC16A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLEC16A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	II,III,IV	+0.626	.001	10	view →
LIHC	Female	II,III,IV	+1.310	<.001	9	view →
STAD	All	II,III,IV	+0.807	<.001	8	view →
THCA	Male	All	+0.500	<.001	8	view →
KIRC	Male	II,III,IV	−0.531	<.001	6	view →
HNSC	All	All	+0.288	.004	5	view →
KICH	All	II,III,IV	+0.436	.009	4	view →
BRCA	All	II,III,IV	+0.299	<.001	4	view →
CHOL	All	All	+1.967	<.001	3	view →
LUSC	All	All	−0.319	<.001	3	view →
PAAD	Female	All	−0.660	.038	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CLEC16A–KIRP

Open the KIRP breakdown →